Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, CureVac N.V’s stock clocked out at $3.78, down -1.82% from its previous closing price of $3.85. In other words, the price has decreased by -$1.82 from its previous closing price. On the day, 0.61 million shares were traded. CVAC stock price reached its highest trading level at $3.885 during the session, while it also had its lowest trading level at $3.7.
Ratios:
To gain a deeper understanding of CVAC’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.38 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.49. For the most recent quarter (mrq), Quick Ratio is recorded 6.19 and its Current Ratio is at 6.20. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on April 25, 2024, Downgraded its rating to Market Perform and sets its target price to $4 from $12 previously.
On June 08, 2023, SVB Securities started tracking the stock assigning a Outperform rating and target price of $13.
UBS Upgraded its Neutral to Buy on January 19, 2023, whereas the target price for the stock was revised from $8 to $18.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 07 ’25 when Myriam Mendila bought 17,839 shares for $4.93 per share.
Pierre Kemula bought 51,523 shares of CVAC for $254,219 on Jan 07 ’25. On Jan 07 ’25, another insider, Alexander Zehnder, who serves as the affiliate of the company, bought 26,104 shares for $4.93 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CVAC now has a Market Capitalization of 847997632 and an Enterprise Value of 700128960. As of this moment, CureVac’s Price-to-Earnings (P/E) ratio for their current fiscal year is 6.96. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.42 while its Price-to-Book (P/B) ratio in mrq is 1.05. Its current Enterprise Value per Revenue stands at 10.631 whereas that against EBITDA is -2.59.
Stock Price History:
The Beta on a monthly basis for CVAC is 2.51, which has changed by 0.05479455 over the last 52 weeks, in comparison to a change of 0.23883796 over the same period for the S&P500. Over the past 52 weeks, CVAC has reached a high of $5.28, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is 15.39%, while the 200-Day Moving Average is calculated to be 17.19%.
Shares Statistics:
It appears that CVAC traded 773.72K shares on average per day over the past three months and 875590 shares per day over the past ten days. A total of 224.34M shares are outstanding, with a floating share count of 93.63M. Insiders hold about 58.26% of the company’s shares, while institutions hold 5.15% stake in the company. Shares short for CVAC as of 1735603200 were 3815960 with a Short Ratio of 4.93, compared to 1732838400 on 4210816. Therefore, it implies a Short% of Shares Outstanding of 3815960 and a Short% of Float of 9.51.
